FIND A DERM    

MIRVASO

Rosacea Redness

Savings & Support

MIRVASO® (brimonidine) topical gel, 0.33%* is the first & only FDA-approved treatment developed and indicated for persistent facial redness of rosacea
/Content/images/home-woman-1.jpg

Not an actual patient. Individual results may vary. Results are simulated to show a 2-grade improvement of the facial redness of rosacea. At hour 12 on day 29, 22% of subjects using MIRVASO experienced a 2-grade improvement of facial redness compared to 9% of people using the vehicle gel.

MIRVASO® (brimonidine) topical gel, 0.33%* is the first and only FDA-approved treatment developed and indicated for persistent facial redness of rosacea. Facial redness is a common symptom of rosacea, a skin condition that affects an estimated 16 million Americans. SEE REAL RESULTS
savings card
sweepstakes contest

Important Safety Information
Indication:  Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.  Adverse Events:  In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis.  Warnings/Precautions:  Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

Phase 3 clinical studies of 553 subjects aged 18 and older. Half of the study participants used MIRVASO and the other half used a gel with no active ingredient (vehicle gel) for 29 days. Subjects and researchers were asked to grade the improvement they saw at 30 minutes and at hours 3, 6, 9, and 12 following application.

Offer not available for uninsured or cash patients. $50 offer is only available to insured patients with coverage for MIRVASO. Insured patients without coverage for MIRVASO may pay no more than $80 for each prescription. Offer excludes Medicaid, Medicare, and federal or state healthcare programs. Maximum benefit to eligible patients does not exceed $200. Certain limitations may apply. See PROGRAM INFORMATION for details.

MIRVASO Cost Reduction Card Program Information

1. Offer not available for uninsured or cash patients.  2. $50 offer is only available to insured patients with coverage for Mirvaso® Gel.  3. Insured patients without coverage for Mirvaso® Gel may pay no more than $80 for each prescription.  4. Maximum benefit to eligible patients does not exceed $200.  5. This offer is not valid if prescriptions are paid by any state or other federally funded programs, including, but not limited to Medicare or Medicaid, Medigap, VA, DOD or TRICARE®.  6. This card is good for use only with a Mirvaso® Gel prescription at the time the prescription is filled by the pharmacist and dispensed to the patient.  7. Offer good only in the USA at participating retail pharmacies and cannot be redeemed at government-subsidized clinics.  8. Galderma Laboratories, L.P. reserves the right to rescind, revoke, or amend this offer without notice at any time.  9. The selling, purchasing, trading, or counterfeiting of this card is prohibited by law.  10. Cash value is 1/100th of 1¢.  11. By using this card, you demonstrate that you understand and agree to comply with the terms and conditions of this offer as set forth on this card.  12. Actual payment for product will depend on individual insurance coverage.

1 of 4
Yes No
2 of 4
Yes No
3 of 4
Yes No
4 of 4
Yes No


You answered yes to questions.

Your facial redness could be related to rosacea.
To know for sure, visit your doctor and discuss your symptoms.


Your answers don't provide enough information to tell you if you could have the
facial redness of rosacea. Talk to your doctor about your symptoms.

Find a Dermatologist:
Next


Important Safety Information
Indication:  Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.  Adverse Events:  In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis.  Warnings/Precautions:  Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Continue to mirvaso.com

MIRVASO Study Description

MIRVASO was tested in 2 medical studies with 553 people aged 18 and older. Half of study participants used MIRVASO and the other half used a gel with no active ingredient for 29 days. Patients and researchers were asked to grade the improvement they saw at hours 3, 6, 9, and 12. On Day 29 of the trials, 2-grade improvement was observed with MIRVASO versus inactive gel at Hour 3 (28% vs 10%), at Hour 6 (28% vs 9%), at Hour 9 (22% vs 10%), and at Hour 12 (22% vs 9%). At 30 minutes on Day 1, 28% of patients using MIRVASO experienced 1-grade improvement of facial redness versus 6% for people using the inactive gel. Individual results with MIRVASO may vary.